ASCLS eNewsBytes

• Hidden Small RNA Determines If Cholera Bacterium Can Infect Humans May 22, 2026
  Scientists have discovered that a small RNA within another gene controls the colonization of the human gut by Vibrio cholerae, the bacterium responsible for cholera. This finding may enhance prediction and prevention strategies for the disease.
• Next-Gen AI-powered Coronary Imaging Platform Receives FDA Clearance, CE Mark May 22, 2026
  Abbott has obtained FDA clearance and CE Mark for its Ultreon 3.0 software, integrating coronary imaging and AI-automated insights to enhance patient outcomes and minimize risks.
• New Study Tracks HIV Care After Hospital Discharge Statewide May 22, 2026
  Efforts to improve linkage to care post-discharge have seen limited success, primarily due to reliance on fragmented or incomplete data. Previous studies often focused on singular health systems, captured only a specific moment in time or lacked detailed insights into the complex factors affecting individuals' ability to maintain care.
• Machine Learning Reveals Common Genetic Cause Behind Unexplained Peripheral Neuropathy May 22, 2026
  Researchers have created a new computational tool capable of accurately identifying genetic issues in the RFC1 gene, associated with specific forms of peripheral neuropathy, a prevalent neurological disorder that leads to pain, sensory loss, imbalance and weakness.
• Arvinas 'Protac' Breast Cancer Drug Cleared by FDA May 22, 2026
  The FDA has approved Arvinas’ protein-degrading medicine, Veppanu, for treating adults with metastatic, estrogen receptor-positive, HER2-negative breast cancer that has progressed after at least one endocrine therapy. Previously known as vepdegestrant, this is the first approval of its kind.